Study wrapper · #972
Weight management treatment in obesity.
Rubio-Herrera MA, Mera-Carreiro S Medicina clinica. 2025.
DOI: 10.1016/j.medcli.2025.107152PubMed: 40865172
SupportedReviewMentions: SemaglutideMentions: TirzepatideMentions: CagrilintideMentions: Retatrutide
Editor's note
A clinical review of obesity pharmacotherapy covering approved and investigational agents. Multiple tracked peptides appear, with reported weight-loss ranges of roughly 15 to 25 percent for the newer combinations and triple agonists. Landscape context rather than primary evidence.
Plain-language abstract
This review surveys current and emerging weight-management drugs, including semaglutide, tirzepatide, cagrilintide, and retatrutide.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026